Research ArticleOriginal Article

Residue substitution enhances the immunogenicity of neoepitopes from gastric cancers

Huahui Yu, Jieyu Li, Yuan Yuan, Yu Chen, Jingwen Hong, Chunmei Ye, Wansong Lin, Huijing Chen, Zengqing Guo, Bo Li and Yunbin Ye
Cancer Biology & Medicine November 2021, 18 (4) 1053-1065; DOI: https://doi.org/10.20892/j.issn.2095-3941.2021.0022

References

  1. 1.↵
    2. Ansell SM,
    3. Lesokhin AM,
    4. Borrello I,
    5. Halwani A,
    6. Scott EC,
    7. Gutierrez M, et al.
    PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015; 372: 311–9.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.
    2. Robert C,
    3. Schachter J,
    4. Long GV,
    5. Arance A,
    6. Grob JJ,
    7. Mortier L, et al.
    Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372: 2521–32.
    OpenUrlCrossRefPubMed
  3. 3.
    2. Topalian SL,
    3. Hodi FS,
    4. Brahmer JR,
    5. Gettinger SN,
    6. Smith DC,
    7. McDermott DF, et al.
    Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443–54.
    OpenUrlCrossRefPubMedWeb of Science
  4. 4.
    2. Herbst RS,
    3. Baas P,
    4. Kim DW,
    5. Felip E,
    6. Pérez-Gracia JL,
    7. Han JY, et al.
    Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387: 1540–50.
    OpenUrlCrossRefPubMed
  5. 5.↵
    2. Kang YK,
    3. Boku N,
    4. Satoh T,
    5. Ryu MH,
    6. Chao Y,
    7. Kato K, et al.
    Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 390: 2461–71.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Rizvi NA,
    3. Hellmann MD,
    4. Snyder A,
    5. Kvistborg P,
    6. Makarov V,
    7. Havel JJ, et al.
    Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348: 124–8.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    2. Hu Z,
    3. Ott PA,
    4. Wu CJ.
    Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018; 18: 168–82.
    OpenUrlCrossRefPubMed
  8. 8.↵
    2. Peng M,
    3. Mo Y,
    4. Wang Y,
    5. Wu P,
    6. Zhang Y,
    7. Xiong F, et al.
    Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019; 18: 128.
    OpenUrlCrossRefPubMed
  9. 9.↵
    2. Cimen Bozkus C,
    3. Roudko V,
    4. Finnigan JP,
    5. Mascarenhas J,
    6. Hoffman R,
    7. Iancu-Rubin C, et al.
    Immune checkpoint blockade enhances shared neoantigen-induced T-cell immunity directed against mutated calreticulin in myeloproliferative neoplasms. Cancer Discov. 2019; 9: 1192–207.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    2. Blankenstein T,
    3. Coulie PG,
    4. Gilboa E,
    5. Jaffee EM.
    The determinants of tumour immunogenicity. Nat Rev Cancer. 2012; 12: 307–13.
    OpenUrlCrossRefPubMed
  11. 11.↵
    2. Li L,
    3. Goedegebuure SP,
    4. Gillanders WE.
    Preclinical and clinical development of neoantigen vaccines. Ann Oncol. 2017; 28: xii11–7.
    OpenUrlPubMed
  12. 12.↵
    2. Bethune MT,
    3. Joglekar AV.
    Personalized T cell-mediated cancer immunotherapy: progress and challenges. Curr Opin Biotechnol. 2017; 48: 142–52.
    OpenUrl
  13. 13.↵
    2. van Rooij N,
    3. van Buuren MM,
    4. Philips D,
    5. Velds A,
    6. Toebes M,
    7. Heemskerk B, et al.
    Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013; 31: e439–42.
    OpenUrlFREE Full Text
  14. 14.↵
    2. Liu XS,
    3. Mardis ER.
    Applications of immunogenomics to cancer. Cell. 2017; 168: 600–12.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. Ott PA,
    3. Hu Z,
    4. Keskin DB,
    5. Shukla SA,
    6. Sun J,
    7. Bozym DJ, et al.
    An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017; 547: 217–21.
    OpenUrlCrossRefPubMed
  16. 16.↵
    2. Sahin U,
    3. Derhovanessian E,
    4. Miller M,
    5. Kloke BP,
    6. Simon P,
    7. Lower M, et al.
    Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017; 547: 222–6.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Anagnostou V,
    3. Smith KN,
    4. Forde PM,
    5. Niknafs N,
    6. Bhattacharya R,
    7. White J, et al.
    Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 2017; 7: 264–76.
    OpenUrlAbstract/FREE Full Text
  18. 18.
    2. Robbins PF,
    3. Lu YC,
    4. El-Gamil M,
    5. Li YF,
    6. Gross C,
    7. Gartner J, et al.
    Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 2013; 19: 747–52.
    OpenUrlCrossRefPubMed
  19. 19.↵
    2. Wei X,
    3. Walia V,
    4. Lin JC,
    5. Teer JK,
    6. Prickett TD,
    7. Gartner J, et al.
    Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet. 2011; 43: 442–6.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Liu S,
    3. Matsuzaki J,
    4. Wei L,
    5. Tsuji T,
    6. Battaglia S,
    7. Hu Q, et al.
    Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. J Immunother Cancer. 2019; 7: 156.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    2. Bjerregaard AM,
    3. Nielsen M,
    4. Hadrup SR,
    5. Szallasi Z,
    6. Eklund AC.
    MuPeXI: prediction of neo-epitopes from tumor sequencing data. Cancer Immunol Immunother. 2017; 66: 1123–30.
    OpenUrlPubMed
  22. 22.↵
    2. Hilf N,
    3. Kuttruff-Coqui S,
    4. Frenzel K,
    5. Bukur V,
    6. Stevanović S,
    7. Gouttefangeas C, et al.
    Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019; 565: 240–5.
    OpenUrlCrossRefPubMed
  23. 23.↵
    2. Keskin DB,
    3. Anandappa AJ,
    4. Sun J,
    5. Tirosh I,
    6. Mathewson ND,
    7. Li S, et al.
    Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019; 565: 234–9.
    OpenUrlPubMed
  24. 24.↵
    2. Kuai R,
    3. Ochyl LJ,
    4. Bahjat KS,
    5. Schwendeman A,
    6. Moon JJ.
    Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 2017; 16: 489–96.
    OpenUrlPubMed
  25. 25.↵
    2. Li H,
    3. Durbin R.
    Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25: 1754–60.
    OpenUrlCrossRefPubMedWeb of Science
  26. 26.↵
    2. Li H,
    3. Handsaker B,
    4. Wysoker A,
    5. Fennell T,
    6. Ruan J,
    7. Homer N, et al.
    The sequence alignment/map format and SAMtools. Bioinformatics. 2009; 25: 2078–9.
    OpenUrlCrossRefPubMedWeb of Science
  27. 27.↵
    2. Szolek A,
    3. Schubert B,
    4. Mohr C,
    5. Sturm M,
    6. Feldhahn M,
    7. Kohlbacher O.
    OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics. 2014; 30: 3310–6.
    OpenUrlCrossRefPubMedWeb of Science
  28. 28.↵
    2. McKenna A,
    3. Hanna M,
    4. Banks E,
    5. Sivachenko A,
    6. Cibulskis K,
    7. Kernytsky A, et al.
    The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010; 20: 1297–303.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    2. Nielsen M,
    3. Lundegaard C,
    4. Lund O,
    5. Keşmir C.
    The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics. 2005; 57: 33–41.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.
    2. Saxová P,
    3. Buus S,
    4. Brunak S,
    5. Keşmir C.
    Predicting proteasomal cleavage sites: a comparison of available methods. Int Immunol. 2003; 15: 781–7.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.↵
    2. Keşmir C,
    3. Nussbaum AK,
    4. Schild H,
    5. Detours V,
    6. Brunak S.
    Prediction of proteasome cleavage motifs by neural networks. Protein Eng. 2002; 15: 287–96.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    2. Tenzer S,
    3. Peters B,
    4. Bulik S,
    5. Schoor O,
    6. Lemmel C,
    7. Schatz MM, et al.
    Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell Mol Life Sci. 2005; 62: 1025–37.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    2. Peters B,
    3. Bulik S,
    4. Tampe R,
    5. van Endert PM,
    6. Holzhütter HG.
    Identifying MHC class I epitopes by predicting the TAP transport efficiency of epitope precursors. J Immunol. 2003; 171: 1741–9.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    2. Calis JJ,
    3. Maybeno M,
    4. Greenbaum JA,
    5. Weiskopf D,
    6. De Silva AD,
    7. Sette A, et al.
    Properties of MHC class I presented peptides that enhance immunogenicity. PLoS Comput Biol. 2013; 9: e1003266.
  35. 35.↵
    2. Salk JJ,
    3. Fox EJ,
    4. Loeb LA.
    Mutational heterogeneity in human cancers: origin and consequences. Annu Rev Pathol. 2010; 5: 51–75.
    OpenUrlCrossRefPubMedWeb of Science
  36. 36.
    2. Martincorena I,
    3. Campbell PJ.
    Somatic mutation in cancer and normal cells. Science. 2015; 349: 1483–9.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    2. Sahin U,
    3. Türeci Ö.
    Personalized vaccines for cancer immunotherapy. Science. 2018; 359: 1355–60.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    2. Chan TA,
    3. Yarchoan M,
    4. Jaffee E,
    5. Swanton C,
    6. Quezada SA,
    7. Stenzinger A, et al.
    Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019; 30: 44–56.
    OpenUrlPubMed
  39. 39.↵
    2. Samstein RM,
    3. Lee CH,
    4. Shoushtari AN,
    5. Hellmann MD,
    6. Shen R,
    7. Janjigian YY, et al.
    Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019; 51: 202–6.
    OpenUrlCrossRefPubMed
  40. 40.↵
    2. Le DT,
    3. Durham JN,
    4. Smith KN,
    5. Wang H,
    6. Bartlett BR,
    7. Aulakh LK, et al.
    Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357: 409–13.
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    2. Tran E,
    3. Robbins PF,
    4. Lu YC,
    5. Prickett TD,
    6. Gartner JJ,
    7. Jia L, et al.
    T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med. 2016; 375: 2255–62.
    OpenUrlCrossRefPubMed
  42. 42.↵
    2. Zacharakis N,
    3. Chinnasamy H,
    4. Black M,
    5. Xu H,
    6. Lu YC,
    7. Zheng Z, et al.
    Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med. 2018; 24: 724–30.
    OpenUrlCrossRefPubMed
  43. 43.↵
    2. Griffith M,
    3. Miller CA,
    4. Griffith OL,
    5. Krysiak K,
    6. Skidmore ZL,
    7. Ramu A, et al.
    Optimizing cancer genome sequencing and analysis. Cell Syst. 2015; 1: 210–23.
    OpenUrl
  44. 44.↵
    2. Chen F,
    3. Zou Z,
    4. Du J,
    5. Su S,
    6. Shao J,
    7. Meng F, et al.
    Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. J Clin Invest. 2019; 129: 2056–70.
    OpenUrlCrossRefPubMed
  45. 45.↵
    2. Zhang SQ,
    3. Ma KY,
    4. Schonnesen AA,
    5. Zhang M,
    6. He C,
    7. Sun E, et al.
    High-throughput determination of the antigen specificities of T cell receptors in single cells. Nat Biotechnol. 2018: PMID30418433.
  46. 46.↵
    2. Sun W,
    3. Wei X,
    4. Niu A,
    5. Ma X,
    6. Li JJ,
    7. Gao D.
    Enhanced anti-colon cancer immune responses with modified eEF2-derived peptides. Cancer Lett. 2015; 369: 112–23.
    OpenUrl
  47. 47.↵
    2. Sun W,
    3. Shi J,
    4. Wu J,
    5. Zhang J,
    6. Chen H,
    7. Li Y, et al.
    A modified HLA-A*0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses. Cell Mol Immunol. 2018; 15: 768–81.
    OpenUrl
  48. 48.↵
    2. Sette A,
    3. Vitiello A,
    4. Reherman B,
    5. Fowler P,
    6. Nayersina R,
    7. Kast WM, et al.
    The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol. 1994; 153: 5586–92.
    OpenUrlAbstract
  49. 49.↵
    2. Dao T,
    3. Korontsvit T,
    4. Zakhaleva V,
    5. Jarvis C,
    6. Mondello P,
    7. Oh C, et al.
    An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules. Oncoimmunology. 2017; 6: e1252895.
  50. 50.↵
    2. Huppa JB,
    3. Gleimer M,
    4. Sumen C,
    5. Davis MM.
    Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol. 2003; 4: 749–55.
    OpenUrlCrossRefPubMedWeb of Science
  51. 51.↵
    2. Yu Z,
    3. Theoret MR,
    4. Touloukian CE,
    5. Surman DR,
    6. Garman SC,
    7. Feigenbaum L, et al.
    Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest. 2004; 114: 551–9.
    OpenUrlCrossRefPubMedWeb of Science
  52. 52.↵
    2. McGranahan N,
    3. Furness AJ,
    4. Rosenthal R,
    5. Ramskov S,
    6. Lyngaa R,
    7. Saini SK, et al.
    Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016; 351: 1463–9.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    2. Jiang Y,
    3. Qiu Y,
    4. Minn AJ,
    5. Zhang NR.
    Assessing intratumor heterogeneity and tracking longitudinal and spatial clonal evolutionary history by next-generation sequencing. Proc Natl Acad Sci U S A. 2016; 113: E5528–37.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    2. Vogelstein B,
    3. Papadopoulos N,
    4. Velculescu VE,
    5. Zhou S,
    6. Diaz LA Jr.,
    7. Kinzler KW.
    Cancer genome landscapes. Science. 2013; 339: 1546–58.
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    2. Schumacher TN,
    3. Schreiber RD.
    Neoantigens in cancer immunotherapy. Science. 2015; 348: 69–74.
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords